Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers.
Target Price
The average target price of ICO.ST is 1.1 and suggests 13% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de
Buy
Sell